1-8 of 8
David Taft
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma

David Taft, Clark Henderson, Christine O'Day, Changpu Yu, Hong Li, Phoenix Ho, Heather Van Epps
Journal: Blood
Blood (2021) 138 (Supplement 1): 1197.
https://doi.org/10.1182/blood-2021-150866
Published: 2021
Journal Articles

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Clinical Trials & Observations
Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana A. Feldman, Ann S. LaCasce, Beth A. Christian, Stephen M. Ansell, Craig H. Moskowitz, Lisa Brown, Chiyu Zhang, David Taft, Sahar Ansari, Mariana Sacchi, Linda Ho, Alex F. Herrera
Journal: Blood
Blood (2021) 138 (6): 427–438.
https://doi.org/10.1182/blood.2020009178
Published: 2021
Includes: Supplemental data
Journal Articles

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Alison J. Moskowitz, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Julie M Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MMSc, Beth A. Christian, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, Lisa Brown, David Taft, Sahar Ansari, Daniel E. Zak, PhD, Mariana Sacchi, MD, Thomas Manley, MD, Alex F. Herrera, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 238.
https://doi.org/10.1182/blood-2019-122576
Published: 2019
Journal Articles

Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine

David Taft, PhD, Tarang Vora, MS, Chen Ren, PhD, Patrick S. Zbyszewski, MBA, Joseph Morgan, MD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Manoj Maniar, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4379.
https://doi.org/10.1182/blood-2018-99-118463
Published: 2018
Journal Articles

Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)

Ranjana H. Advani, MD, Alison J. Moskowitz, MD, Nancy L. Bartlett, MD, Julie M. Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MSc, Beth A. Christian, MD, Stephen M. Ansell, MD PhD, Craig H. Moskowitz, MD, Keenan Fenton, Carol Anne Ogden, PhD, David Taft, Daniel E. Zak, PhD, Mariana Sacchi, MD, Faith Galderisi, DO, Alex F. Herrera, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1635.
https://doi.org/10.1182/blood-2018-99-110002
Published: 2018
Journal Articles

Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials

Manoj Maniar, PhD, Chen Ren, PhD, Patrick S. Zbyszewski, MBA, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, David Taft, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3106.
https://doi.org/10.1182/blood-2018-99-116982
Published: 2018
Journal Articles

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Clinical Trials & Observations
Alex F. Herrera, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana A. Feldman, Ann S. LaCasce, Stephen M. Ansell, Craig H. Moskowitz, Keenan Fenton, Carol Anne Ogden, David Taft, Qu Zhang, Kazunobu Kato, Mary Campbell, Ranjana H. Advani
Journal: Blood
Blood (2018) 131 (11): 1183–1194.
https://doi.org/10.1182/blood-2017-10-811224
Published: 2018
Includes: Supplemental data
Journal Articles

Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, MD, Alison J. Moskowitz, MD, Nancy L. Bartlett, MD, Julie M Vose, MD, Radhakrishnan Ramchandren, MD, Tatyana A Feldman, MD, Ann S LaCasce, MD MSc, Stephen M Ansell, MD PhD, Craig H. Moskowitz, MD, Keenan Fenton, Carol Anne Ogden, David Taft, Qu Zhang, Kazunobu Kato, Mary Campbell, MD, Ranjana H. Advani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 649.
https://doi.org/10.1182/blood.V130.Suppl_1.649.649
Published: 2017